Skip to Main Content

Author Details

Mark M Pomerantz
Dana-Farber Cancer Institute
2007
109
37
PMIDPaper TitleJournal TitlePublished Year
37462445TERT Promoter Mutations Frequency Across Race, Sex, and Cancer Type.Oncologist2024
38049623Author Correction: Liquid biopsy epigenomic profiling for cancer subtyping.Nat Med2024
37462445TERT Promoter Mutations Frequency Across Race, Sex, and Cancer Type.Oncologist2024
38049623Author Correction: Liquid biopsy epigenomic profiling for cancer subtyping.Nat Med2024
36018819Clonal hematopoiesis and risk of prostate cancer in large samples of European ancestry men.Hum Mol Genet2023
36018819Clonal hematopoiesis and risk of prostate cancer in large samples of European ancestry men.Hum Mol Genet2023
37857693Author Correction: A biallelic multiple nucleotide length polymorphism explains functional causality at 5p15.33 prostate cancer risk locus.Nat Commun2023
37733980Pretest Video Education Versus Genetic Counseling for Patients With Prostate Cancer: ProGen, A Multisite Randomized Controlled Trial.JCO Oncol Pract2023
37733366Germline Sequencing Analysis to Inform Clinical Gene Panel Testing for Aggressive Prostate Cancer.JAMA Oncol2023
37865722Liquid biopsy epigenomic profiling for cancer subtyping.Nat Med2023
37612286A biallelic multiple nucleotide length polymorphism explains functional causality at 5p15.33 prostate cancer risk locus.Nat Commun2023
37271632Grade Group 1 Prostate Cancers Exhibit Tumor-defining Androgen Receptor-driven Programs.Eur Urol2023
37267579Early Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer.J Clin Oncol2023
36702553Clinical Implementation of <sup>177</sup>Lu-PSMA-617 in the United States: Lessons Learned and Ongoing Challenges.J Nucl Med2023
36865297Enhancer profiling identifies epigenetic markers of endocrine resistance and reveals therapeutic options for metastatic castration-resistant prostate cancer patients.medRxiv2023
36993558Analysis of evolutionary dynamics and clonal architecture in prostate cancer.bioRxiv2023
36681680Epigenomic charting and functional annotation of risk loci in renal cell carcinoma.Nat Commun2023
37865722Liquid biopsy epigenomic profiling for cancer subtyping.Nat Med2023
37857693Author Correction: A biallelic multiple nucleotide length polymorphism explains functional causality at 5p15.33 prostate cancer risk locus.Nat Commun2023
37612286A biallelic multiple nucleotide length polymorphism explains functional causality at 5p15.33 prostate cancer risk locus.Nat Commun2023
37733980Pretest Video Education Versus Genetic Counseling for Patients With Prostate Cancer: ProGen, A Multisite Randomized Controlled Trial.JCO Oncol Pract2023
37733366Germline Sequencing Analysis to Inform Clinical Gene Panel Testing for Aggressive Prostate Cancer.JAMA Oncol2023
36993558Analysis of evolutionary dynamics and clonal architecture in prostate cancer.bioRxiv2023
37271632Grade Group 1 Prostate Cancers Exhibit Tumor-defining Androgen Receptor-driven Programs.Eur Urol2023
37267579Early Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer.J Clin Oncol2023
36681680Epigenomic charting and functional annotation of risk loci in renal cell carcinoma.Nat Commun2023
36865297Enhancer profiling identifies epigenetic markers of endocrine resistance and reveals therapeutic options for metastatic castration-resistant prostate cancer patients.medRxiv2023
36702553Clinical Implementation of <sup>177</sup>Lu-PSMA-617 in the United States: Lessons Learned and Ongoing Challenges.J Nucl Med2023
34907080Detecting Neuroendocrine Prostate Cancer Through Tissue-Informed Cell-Free DNA Methylation Analysis.Clin Cancer Res2022
36103646Addition of Germline Testing to Tumor-Only Sequencing Improves Detection of Pathogenic Germline Variants in Men With Advanced Prostate Cancer.JCO Precis Oncol2022
35509021Androgen receptor reprogramming demarcates prognostic, context-dependent gene sets in primary and metastatic prostate cancer.Clin Epigenetics2022
35562350MYC drives aggressive prostate cancer by disrupting transcriptional pause release at androgen receptor targets.Nat Commun2022
36071171Genetic determinants of chromatin reveal prostate cancer risk mediated by context-dependent gene regulation.Nat Genet2022
35731919The Prostate Cancer Androgen Receptor Cistrome in African American Men Associates with Upregulation of Lipid Metabolism and Immune Response.Cancer Res2022
35603787Response to supraphysiological testosterone is predicted by a distinct androgen receptor cistrome.JCI Insight2022
34907080Detecting Neuroendocrine Prostate Cancer Through Tissue-Informed Cell-Free DNA Methylation Analysis.Clin Cancer Res2022
35075214Metabolic syndrome and its pharmacologic treatment are associated with the time to castration-resistant prostate cancer.Prostate Cancer Prostatic Dis2022
35509021Androgen receptor reprogramming demarcates prognostic, context-dependent gene sets in primary and metastatic prostate cancer.Clin Epigenetics2022
35731919The Prostate Cancer Androgen Receptor Cistrome in African American Men Associates with Upregulation of Lipid Metabolism and Immune Response.Cancer Res2022
35603787Response to supraphysiological testosterone is predicted by a distinct androgen receptor cistrome.JCI Insight2022
35562350MYC drives aggressive prostate cancer by disrupting transcriptional pause release at androgen receptor targets.Nat Commun2022
36071171Genetic determinants of chromatin reveal prostate cancer risk mediated by context-dependent gene regulation.Nat Genet2022
36103646Addition of Germline Testing to Tumor-Only Sequencing Improves Detection of Pathogenic Germline Variants in Men With Advanced Prostate Cancer.JCO Precis Oncol2022
35075214Metabolic syndrome and its pharmacologic treatment are associated with the time to castration-resistant prostate cancer.Prostate Cancer Prostatic Dis2022
32853339Germline Sequencing DNA Repair Genes in 5545 Men With Aggressive and Nonaggressive Prostate Cancer.J Natl Cancer Inst2021
33956343A polymorphism in the promoter of FRAS1 is a candidate SNP associated with metastatic prostate cancer.Prostate2021
33899001EZH2 inhibition activates a dsRNA-STING-interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer.Nat Cancer2021
33683939Results of a Randomized Phase II Trial of Intense Androgen Deprivation Therapy prior to Radical Prostatectomy in Men with High-Risk Localized Prostate Cancer.J Urol2021
33789101Trans-ethnic variation in germline variants of patients with renal cell carcinoma.Cell Rep2021
33785741Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer.Nat Commun2021
  • 1 - 50 of 218

Recommended Authors

Sinja Taavitsainen
Prostate Cancer Research Center, Tampere University and Tays Cancer Center
Career Start Year 2018
Number of shared co-authors 9
Wei Yuan
The Institute for Cancer Research
Career Start Year 2015
Number of shared co-authors 22
Matti Annala
University of British Columbia
Career Start Year 2011
Number of shared co-authors 31
Alec Paschalis
The Institute for Cancer Research
Career Start Year 2009
Number of shared co-authors 6
Alexander W Wyatt
University of British Columbia
Career Start Year 2007
Number of shared co-authors 44
Mitchell G Lawrence
Biomedicine Discovery Institute, Monash University
Career Start Year 2005
Number of shared co-authors 16
Thorsten Schlomm
Charite - University Hospital Berlin
Career Start Year 2004
Number of shared co-authors 31
Mine S Cicek
Mayo Clinic
Career Start Year 2004
Number of shared co-authors 30
Gerhardt Attard
The Institute of Cancer Research
Career Start Year 2004
Number of shared co-authors 54
Channing J Paller
Johns Hopkins University School of Medicine
Career Start Year 2004
Number of shared co-authors 20
Scott A Tomlins
Rogel Cancer Center, University of Michigan Medical School ann arbor
Career Start Year 2003
Number of shared co-authors 59
Adam Foye
University of California San Francisco
Career Start Year 2003
Number of shared co-authors 24
Charlie E Massie
University of Cambridge
Career Start Year 2003
Number of shared co-authors 19
Christopher E Barbieri
Weill Cornell Medical College
Career Start Year 2003
Number of shared co-authors 33
Daniel Leongamornlert
Oncogenetics Team The Institute of Cancer Research London UK.
Career Start Year 2003
Number of shared co-authors 53
Wassim Abida
Memorial Sloan Kettering Cancer Center
Career Start Year 2002
Number of shared co-authors 40
Antonio Hurtado-Coll
University of British Columbia
Career Start Year 2002
Number of shared co-authors 48
Heather H Cheng
Fred Hutchinson Cancer Center, University of Washington
Career Start Year 2002
Number of shared co-authors 43
Ladan Fazli
University of British Columbia
Career Start Year 2002
Number of shared co-authors 54
Mark C Markowski
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Career Start Year 2001
Number of shared co-authors 16
Joshi J Alumkal
Rogel Cancer Center, University of Michigan ann arbor
Career Start Year 1999
Number of shared co-authors 38
Srinivasan Yegnasubramanian
Johns Hopkins University School of Medicine
Career Start Year 1999
Number of shared co-authors 33
Hayley C Whitaker
University College London
Career Start Year 1999
Number of shared co-authors 20
Franklin W Huang
Institute for Human Genetics, University of California san francisco
Career Start Year 1998
Number of shared co-authors 43
Joaquin Mateo
Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital Campus
Career Start Year 1997
Number of shared co-authors 32
Phillip G Febbo
Illumina Inc.
Career Start Year 1997
Number of shared co-authors 30
Arul M Chinnaiyan
University of Michigan Medical School.
Career Start Year 1993
Number of shared co-authors 69
Bruce Montgomery
Fred Hutchinson Cancer Center, University of Washington
Career Start Year 1990
Number of shared co-authors 43
Mark A Rubin
University of Bern
Career Start Year 1990
Number of shared co-authors 79
George Steven Bova
Prostate Cancer Research Center, Tampere University and Tays Cancer Center
Career Start Year 1982
Number of shared co-authors 28

Collaborators

Matthew L Freedman
Dana-Farber Cancer Institute
Co-authored papers 61
Philip W Kantoff
Memorial Sloan Kettering Cancer Center
Co-authored papers 35
Toni K Choueiri
Dana-Farber Cancer Institute
Co-authored papers 23
Mary-Ellen Taplin
Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute
Co-authored papers 17
William K Oh
Co-authored papers 16
Connor Bell
Dana-Farber Cancer Institute
Co-authored papers 13
Sylvan C Baca
Co-authored papers 13
Meredith M Regan
Co-authored papers 12
Lorelei A Mucci
Co-authored papers 12
Edward O'Connor
Dana-Farber Cancer Institute
Co-authored papers 11
Stephen J Chanock
National Cancer Institute, National Institutes of Health
Co-authored papers 10
Douglas F Easton
University of Cambridge
Co-authored papers 9
Christopher A Haiman
University of Southern California
Co-authored papers 8
Paul L Nguyen
Brigham and Women's Hospital and Dana Farber Cancer Institute, Harvard Medical School
Co-authored papers 8
Massimo Loda
Weill Medical College of Cornell University
Co-authored papers 8
Stephanie J Weinstein
Co-authored papers 8
Myles Brown
Co-authored papers 8
Demetrius Albanes
Co-authored papers 8
Alexander Gusev
The Center for Functional Cancer Epigenetics, Dana Farber Cancer Institute
Co-authored papers 7
Sonja I Berndt
Co-authored papers 7
Oliver Sartor
Tulane University School of Medicine
Co-authored papers 7
Kathryn L Penney
Co-authored papers 7
Eliezer M Van Allen
Dana-Farber Cancer Institute
Co-authored papers 6
Fredrik Wiklund
Co-authored papers 6
Eva Corey
University of Washington School of Medicine
Co-authored papers 6
Anthony V D'Amico
Duke University Medical Center
Co-authored papers 6
Meredith Yeager
Frederick National Laboratory for Cancer Research
Co-authored papers 6
Cezary Cybulski
International Hereditary Cancer Center, Pomeranian Medical University
Co-authored papers 5
Zsofia Kote-Jarai
The Institute of Cancer Research
Co-authored papers 5
Janet L Stanford
Fred Hutchinson Cancer Research Center
Co-authored papers 5
Release 1.2